Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2267582 | 0.72 | TSHR (0.56) | MAPK14MAPK8 | |
| SCHEMBL6488266 | 0.71 | MAPK14 (0.54) | MAPK14MAPK13MAPK8MAPK12MAPK10 | |
| SCHEMBL6488932 | 0.71 | MAPK14 (0.54) | MAPK14MAPK13MAPK8MAPK12MAPK10 | |
| SCHEMBL6478990 | 0.71 | MAPK14 (0.54) | MAPK14MAPK13MAPK8MAPK12MAPK10 | |
| SCHEMBL6480150 | 0.71 | MAPK14 (0.54) | MAPK14MAPK13MAPK8MAPK12MAPK10 | |
| SCHEMBL6488935 | 0.71 | MAPK14 (0.54) | MAPK14MAPK13MAPK8MAPK12MAPK10 | |
| SCHEMBL6480144 | 0.71 | MAPK14 (0.54) | MAPK14MAPK13MAPK8MAPK12MAPK10 | |
| SCHEMBL6490431 | 0.71 | MAPK14 (0.67) | MAPK14 | |
| SCHEMBL6480679 | 0.71 | MAPK14 (0.71) | MAPK14 | |
| SCHEMBL6488506 | 0.70 | MAPK14 (0.65) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919346-B2 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-6790846-B2 | SUCH AS 2-ETHYOXYMETHYL-4-(4-FLOUROPHENYL)-3-PYRIDIN-4-YL-2H-ISOXAZOL-5-ONE FOR INHIBITION OF THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR; TREATMENT OF ARTHRITIS AND CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY | 2004-09-14 | — | — | US | disclosed |
| US-20040122025-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | THE PROCTER & GAMBLE COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1392299-A1 | ISOXAZOLONE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY | THE PROCTER & GAMBLE COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030096814-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-05-22 | — | — | US | disclosed |
| WO-2002094266-A1 | ISOXAZOLONE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096814-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | TNF, IL5, GPR35 | MAPK14 1280/4885MAPK13 2833/4885MAPK8 1808/4885 |
| US-20040122025-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | TNF, IL5, GPR35 | MAPK14 1280/4885MAPK13 2833/4885MAPK8 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.